BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23045585)

  • 21. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
    Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ
    Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022
    [No Abstract]   [Full Text] [Related]  

  • 22. Update on the Treatment of Anaplastic Large Cell Lymphoma.
    Vu K; Ai W
    Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
    Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
    Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
    Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J
    Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
    Crescenzo R; Abate F; Lasorsa E; Tabbo' F; Gaudiano M; Chiesa N; Di Giacomo F; Spaccarotella E; Barbarossa L; Ercole E; Todaro M; Boi M; Acquaviva A; Ficarra E; Novero D; Rinaldi A; Tousseyn T; Rosenwald A; Kenner L; Cerroni L; Tzankov A; Ponzoni M; Paulli M; Weisenburger D; Chan WC; Iqbal J; Piris MA; Zamo' A; Ciardullo C; Rossi D; Gaidano G; Pileri S; Tiacci E; Falini B; Shultz LD; Mevellec L; Vialard JE; Piva R; Bertoni F; Rabadan R; Inghirami G;
    Cancer Cell; 2015 Apr; 27(4):516-32. PubMed ID: 25873174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK-positive lymphoma: a single disease with a broad spectrum of morphology.
    Benharroch D; Meguerian-Bedoyan Z; Lamant L; Amin C; Brugières L; Terrier-Lacombe MJ; Haralambieva E; Pulford K; Pileri S; Morris SW; Mason DY; Delsol G
    Blood; 1998 Mar; 91(6):2076-84. PubMed ID: 9490693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas.
    Sorigue M; Kuittinen O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
    Ngu HS; Savage KJ
    Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
    Gordon MJ; Duan Z; Zhao H; Nastoupil L; Ng S; Danilov AV; Iyer S; Giordano SH
    Leuk Lymphoma; 2023 Dec; 64(14):2258-2268. PubMed ID: 37706491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK-positive anaplastic large cell lymphoma in adults.
    Gromowsky MJ; D'Angelo CR; Lunning MA; Armitage JO
    Fac Rev; 2023; 12():21. PubMed ID: 37655119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
    Hapgood G; Civallero M; Stepanishyna Y; Vose J; Cabrera ME; Advani RH; Pileri SA; Manni M; Horwitz SM; Foss FM; Hitz F; Radford J; Dlouhy I; Chiattone C; Kim WS; Skrypets T; Nagler A; Trotman J; Luminari S; Federico M
    Blood Adv; 2023 Sep; 7(17):5047-5054. PubMed ID: 37163360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK-negative anaplastic large cell lymphoma with
    Sibon D; Bisig B; Bonnet C; Poullot E; Bachy E; Cavalieri D; Fataccioli V; Bregnard C; Drieux F; Bruneau J; Lemonnier F; Dupuy A; Bossard C; Parrens M; Bouabdallah K; Ketterer N; Berthod G; Cairoli A; Damaj G; Tournilhac O; Jais JP; Gaulard P; De Leval L
    Haematologica; 2023 Jun; 108(6):1590-1603. PubMed ID: 36453105
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
    Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary Anaplastic Lymphoma Kinase (ALK)-Negative Anaplastic Large Cell Lymphoma (ALCL) Presenting as Perforation Peritonitis: A Case Report and Management Principles.
    Sanker V; Mohamed A; Pranala M; Jadhav C; Tharakan V
    Cureus; 2022 Sep; 14(9):e28738. PubMed ID: 36211108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin.
    Cranmer H; Trueman D; Evers E; Woodcock F; Podkonjak T
    Pharmacoecon Open; 2022 Nov; 6(6):881-892. PubMed ID: 36057890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
    Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
    J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral T-Cell Lymphomas: Therapeutic Approaches.
    Sibon D
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.